Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucentis vs PRP in High Risk Proliferative Diabetic Retinopathy
NCT01280929Phase 2Completed
- Start
- Sep 2010
- Primary completion
- Dec 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in proliferative diabetic retinopathy (PDR). Started Sep 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01280929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01280929.